Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$97.75 USD

97.75
409,224

+0.17 (0.17%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $97.84 +0.09 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View

Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.

Amedisys (AMED) Beats Q3 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 12.50% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LHC Group (LHCG) Finalizes Home Health & Hospice Buyout Deals

LHC Group (LHCG) to expand in Virginia Beach with the completion of the previously announced acquisition agreements with two providers, one in home health and the other in hospice.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Amedisys (AMED) Down 6.5% Since Last Earnings Report: Can It Rebound?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sapna Bagaria headshot

Encompass Health's (EHC) Growth View Makes It a Good Buy

Ageing population, building of hospitals and other operational efforts poise Encompass Health (EHC) well for long-term growth, thus making it a good investment option.

EHC vs. AMED: Which Stock Should Value Investors Buy Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

EHC vs. AMED: Which Stock Should Value Investors Buy Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic

The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow

Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.

Amedisys (AMED) Beats Q2 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 3.05% and -0.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio

Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.

Amedisys (AMED) Latest New York Assets Buyout Aids Home Health

The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice

Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.

Encompass Health (EHC) to Expand Inpatient Rehabilitation Unit

Encompass Health (EHC) to construct an inpatient rehabilitation hospital to capture a market with great prospects.

Amedisys (AMED) Soars 6.7%: Is Further Upside Left in the Stock?

Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Amedisys' (AMED) Contessa Buyout to Boost Home Health Business

Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.

DVA or AMED: Which Is the Better Value Stock Right Now?

DVA vs. AMED: Which Stock Is the Better Value Option?